Literature DB >> 30898700

Screening of acetaminophen-induced alterations in epithelial-to-mesenchymal transition-related expression of microRNAs in a model of stem-like triple-negative breast cancer cells: The possible functional impacts.

Elham Afshar1, Masoud Hashemi-Arabi2, Siamak Salami3, Tahmineh Peirouvi4, Ramin Pouriran5.   

Abstract

Current protocols for therapy inefficiently targets triple negative breast cancer and barely eradicate cancer stem cells. Elucidation of the pleiotropic effect of clinically proven therapeutics on cancer cells shed light on novel application of old friends. The pleiotropic effect of acetaminophen (APAP) on breast cancer was previously reported. In a cell model of triple negative breast cancer with stem-like CD44high/CD24low phenotype, we screened the impacts of APAP (1 mM, 72 h) on the Epithelial to mesenchymal transition (EMT)-related expression of miRs. APAP significantly overexpressed hsa-miR-130a-3p, 192-5p, 214-3p, 101-3p, 30d-5p, 10a-5p, 99a-5p, 200c-3p, 143-3p, 30b-5p and let-7f-5p showed significant overexpression, but suppressed the expression of hsa-miR-7-5p, 149-3p, 215, 150-5p, 205-5p, 206, 10b-5p, 20b-5p, 145-5p, 26b-5p, 223-3p, 17-5p, 186-5p, 146a-5p and let-7c. It also altered on the expression of selected EMT-related genes, significantly upregulated the expression of KRT19, AKT2, CD24, and TIMP1; but downregulated the expression of MMP2, ALDH1, MMP9, TWIST, NOTCH1, and AKT1. Such shifts in expression profiles increased the population of the cells with CD44high/CD24high, and CD44low/CD24high phenotypes, significantly reduced the Twist protein and shifted the balance of E-cadherin and Vimentin proteins in favor of differentiation. Treated cells showed a significant reduction of in vitro migration and were significantly chemosensitized to Camptothecin. In conclusion, APAP, at a safe clinical dose, induced a set of targeted alterations in the EMT-related miRs which implicate, even in part, significant mitigation in chemoresistance and in vitro migration. Further studies should also be piloted to elucidate the most crucial miRs and to evaluate its clinical effectiveness.
Copyright © 2019 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  Acetaminophen; Cancer stem cells; Epithelial to mesenchymal transition; Triple-negative breast cancer; microRNA expression profile

Mesh:

Substances:

Year:  2019        PMID: 30898700     DOI: 10.1016/j.gene.2019.02.106

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  5 in total

Review 1.  Breast cancer stem cells: A review of their characteristics and the agents that affect them.

Authors:  Naing L Shan; Yoosub Shin; Ge Yang; Philip Furmanski; Nanjoo Suh
Journal:  Mol Carcinog       Date:  2021-01-11       Impact factor: 4.784

2.  Epithelial to mesenchymal transition and microRNA expression are associated with spindle and apocrine cell morphology in triple-negative breast cancer.

Authors:  Marketa Koleckova; Jiri Ehrmann; Jan Bouchal; Maria Janikova; Aneta Brisudova; Josef Srovnal; Katerina Staffova; Marek Svoboda; Ondrej Slaby; Lenka Radova; Katherine Vomackova; Bohuslav Melichar; Lucia Veverkova; Zdenek Kolar
Journal:  Sci Rep       Date:  2021-03-04       Impact factor: 4.379

3.  ET-1 Promotes Epithelial-Mesenchymal Transition in Oral Squamous Cell Carcinoma Cells via the microRNA-489-3p /TWIST Axis.

Authors:  Huey-En Tzeng; Chih-Hsin Tang; Chun-Hao Tsai; Chih-Hui Chiu; Min-Huan Wu; Yun Yen
Journal:  Onco Targets Ther       Date:  2021-10-06       Impact factor: 4.147

4.  Integrating UPLC-HR-MS/MS, Network Pharmacology, and Experimental Validation to Uncover the Mechanisms of Jin'gan Capsules against Breast Cancer.

Authors:  Jianfei Qiu; Zhiyin Zhang; Anling Hu; Peng Zhao; Xuenai Wei; Hui Song; Jue Yang; Yanmei Li
Journal:  ACS Omega       Date:  2022-08-07

5.  Targeted Therapy Modulates the Secretome of Cancer-Associated Fibroblasts to Induce Resistance in HER2-Positive Breast Cancer.

Authors:  Melani Luque; Marta Sanz-Álvarez; Andrea Santamaría; Sandra Zazo; Ion Cristóbal; Lorena de la Fuente; Pablo Mínguez; Pilar Eroles; Ana Rovira; Joan Albanell; Juan Madoz-Gúrpide; Federico Rojo
Journal:  Int J Mol Sci       Date:  2021-12-10       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.